Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAV-003
- Development stage
- Preclinical
- Lead developer
- Navrogen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NAV-003 is a humanized divalent bispecific IgG antibody developed by Navrogen Inc. that targets mesothelin (MSLN) and the CD3ε subunit of the T-cell receptor. The antibody is designed to bind to a unique epitope within region III (amino acids 525-560) of mesothelin, which is located proximal to the tumor cell surface. By simultaneously engaging MSLN-expressing tumor cells and CD3 on T cells, NAV-003 activates and redirects T cells to elicit robust CD3-redirected T-cell mediated cytotoxicity. Preclinical studies have demonstrated efficacy against patient-derived mesothelioma xenografts, supporting its development for various MSLN-positive malignancies, including mesothelioma, lung adenocarcinoma, breast, and colon cancers.
- Other names
- NAV-003-Navrogen-MSLN (mesothelin)-bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Mesothelin
Beyond the preview
Go deeper on NAV-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAV-003.